An Insight Into the Complexity of Multiple Myeloma: Case Study

Multiple myeloma is a malignant disorder of plasma cells—specialized B lymphocytes responsible for producing antibodies essential to immune function. Also referred to as plasma cell myeloma, myelomatosis, or Kahler's disease, it is typically manageable but rarely curable. The condition is characterized by the clonal proliferation of abnormal plasma cells, primarily within the bone marrow. Although bone involvement is common, multiple myeloma must be distinguished from metastatic cancers originating in organs such as the breast or lung that secondarily affect the skeleton. Accounting for roughly 1% of all cancers, multiple myeloma is relatively uncommon, with an estimated incidence of 40 cases per year per million individuals. While earlier reports suggested a two- to threefold rise in incidence over the past 40 years, robust epidemiological studies from the United States and Europe indicate that this trend is largely due to improved diagnostic capabilities and greater access to healthcare, rather than a true increase in disease prevalence.